{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:19:25Z","timestamp":1787314765143,"version":"build-2736575974"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) represents a global health challenge. Berberine, an isoquinoline alkaloid traditionally used for metabolic disorders, has garnered attention for its potential therapeutic interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To comprehensively review and perform a meta-analysis of berberine\u2019s effects on NAFLD across clinical and preclinical studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was conducted across five databases from their inception to May 2024. We included randomized controlled trials and animal studies that evaluated berberine\u2019s impact on NAFLD using specified biochemical markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 487 screened studies, 22 (4 clinical and 18 preclinical) were included. Clinically, berberine significantly reduced fasting blood glucose (FBG) levels, with an effect size of 0.53 (95% CI: 0.04\u20131.01). In preclinical settings, berberine consistently demonstrated benefits across several markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipid profiles, despite significant heterogeneity in some outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Berberine presents promising therapeutic avenues for NAFLD management, especially in terms of glucose metabolism. Further rigorous, well-designed trials are needed to substantiate these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , Identifier CRD42023459618.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1460643","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:41:41Z","timestamp":1756453301000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research"],"prefix":"10.3389","volume":"16","author":[{"given":"Wenyu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"9381","DOI":"10.1038\/s41598-024-60103-9","article-title":"Intelligent berberine-loaded erythrocytes attenuated inflammatory cytokine productions in macrophages","volume":"14","author":"Aghili","year":"2024","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"631100","DOI":"10.3389\/fphar.2021.631100","article-title":"A new therapeutic candidate for cardiovascular diseases: berberine","volume":"12","author":"Cai","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jep.2013.07.025","article-title":"Berberine metabolites exhibit triglyceride-lowering effects via activation of AMP-activated protein kinase in Hep G2 cells","volume":"149","author":"Cao","year":"2013","journal-title":"J. Ethnopharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1194\/jlr.M001958","article-title":"Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats","volume":"51","author":"Chang","year":"2010","journal-title":"J. Lipid. Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1476-511X-11-86","article-title":"The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet","volume":"11","author":"Chang","year":"2012","journal-title":"Lipids Health Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12967-016-0982-x","article-title":"Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease","volume":"14","author":"Chang","year":"2016","journal-title":"J. Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3892\/etm.2021.10543","article-title":"Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR","volume":"22","author":"Chen","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.3892\/etm.2019.7208","article-title":"Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2\/ARE signalling pathway","volume":"17","author":"Deng","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.biopha.2018.01.071","article-title":"Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin","volume":"99","author":"Feng","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.7150\/thno.30787","article-title":"Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics","volume":"9","author":"Feng","year":"2019","journal-title":"Theranostics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13543784.2017.1312339","article-title":"PPAR-\u03b1 agonists are still on the rise: an update on clinical and experimental findings","volume":"26","author":"Ferri","year":"2017","journal-title":"Expert Opin. Investig. Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"673","DOI":"10.7150\/ijbs.7.673","article-title":"Berberine regulated Gck, G6pc, Pck1 and Srebp-1c expression and activated AMP-activated protein kinase in primary rat hepatocytes","volume":"7","author":"Ge","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"22612","DOI":"10.1038\/srep22612","article-title":"Berberine ameliorates hepatic steatosis and Suppresses liver and adipose tissue inflammation in mice with diet-induced obesity","volume":"6","author":"Guo","year":"2016","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"104722","DOI":"10.1016\/j.phrs.2020.104722","article-title":"Berberine pharmacology and the gut microbiota: a hidden therapeutic link","volume":"155","author":"Habtemariam","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/JME-16-0139","article-title":"ERK-dependent mTOR pathway is involved in berberine-induced autophagy in hepatic steatosis","volume":"57","author":"He","year":"2016","journal-title":"J. Mol. Endocrinol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/ptr.3204","article-title":"Berberine inhibits SREBP-1-related clozapine and risperidone induced adipogenesis in 3T3-L1 cells","volume":"24","author":"Hu","year":"2010","journal-title":"Phytother. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"106481","DOI":"10.1016\/j.phrs.2022.106481","article-title":"Protective effect of berberine in diabetic nephropathy: a systematic review and meta-analysis revealing the mechanism of action","volume":"185","author":"Hu","year":"2022","journal-title":"Pharmacol. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"110137","DOI":"10.1016\/j.biopha.2020.110137","article-title":"The effect of Berberine on weight loss in order to prevent obesity: a systematic review","volume":"127","author":"Ilyas","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7777","DOI":"10.3748\/wjg.v21.i25.7777","article-title":"Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats","volume":"21","author":"Jiang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.2174\/0113892010283237240107121749","article-title":"Anti-seizure effects and mechanisms of berberine: a systematic review","volume":"25","author":"Jivad","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.4103\/pm.pm_584_16","article-title":"Amelioration of Intestinal Barrier Dysfunction by berberine in the treatment of nonalcoholic fatty liver disease in rats","volume":"13","author":"Li","year":"2017","journal-title":"Pharmacogn. Mag."},{"key":"B24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fphar.2020.00351","article-title":"The impacts of Herbal medicines and Natural products on regulating the hepatic lipid metabolism","volume":"11","author":"Li","year":"","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"109563","DOI":"10.1016\/j.biopha.2019.109563","article-title":"Berberine increases glucose uptake and intracellular ROS levels by promoting Sirtuin 3 ubiquitination","volume":"121","author":"Li","year":"","journal-title":"Biomed. Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12865-020-00358-9","article-title":"Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway","volume":"21","author":"Lu","year":"","journal-title":"BMC Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1021\/acs.jnatprod.6b00558","article-title":"Pterosin Sesquiterpenoids from Pteris cretica as Hypolipidemic Agents via activating liver X receptors","volume":"79","author":"Luo","year":"2016","journal-title":"J. Nat. Prod."},{"key":"B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.47176\/mjiri.36.39","article-title":"The effect of berberine on lipid profile, liver enzymes, and fasting blood glucose in patients with non-alcoholic fatty liver disease (NAFLD): a randomized controlled trial","volume":"36","author":"Nejati","year":"2022","journal-title":"Med. J. Islam Repub. Iran."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.cgh.2024.07.003","article-title":"Expert Panel Recommendations: Practical clinical applications for Initiating and Monitoring Resmetirom in patients with MASH\/NASH and moderate to Noncirrhotic advanced fibrosis","volume":"22","author":"Noureddin","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ptr.6217","article-title":"Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-\u03baB and AMPK signaling pathways","volume":"33","author":"Pei","year":"2019","journal-title":"Phytother. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.7150\/thno.30640","article-title":"Berberine Protects Glomerular Podocytes via inhibiting Drp1-mediated mitochondrial Fission and Dysfunction","volume":"9","author":"Qin","year":"2019","journal-title":"Theranostics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrgastro.2016.3","article-title":"Management of NAFLD: a stage-based approach","volume":"13","author":"Rinella","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/ptr.8077","article-title":"Anti-inflammatory, antioxidant, and immunomodulatory effects of Berberis vulgaris and its constituent berberine, experimental and clinical, a review","volume":"38","author":"Shakeri","year":"2024","journal-title":"Phytother. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11684-019-0724-6","article-title":"Biological properties and clinical applications of berberine","volume":"14","author":"Song","year":"2020","journal-title":"Front. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"902","DOI":"10.5152\/tjg.2020.19568","article-title":"Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4\/MyD88\/NF-\u03baB pathway","volume":"31","author":"Wang","year":"2020","journal-title":"Turk. J. Gastroenterol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"goad032","DOI":"10.1093\/gastro\/goad032","article-title":"Berberine alleviates non-alcoholic hepatic steatosis partially by promoting SIRT1 deacetylation of CPT1A in mice","volume":"11","author":"Wang","year":"2023","journal-title":"Gastroenterol. Rep."},{"key":"B38","doi-asserted-by":"publisher","first-page":"155258","DOI":"10.1016\/j.phymed.2023.155258","article-title":"Inhibition of inflammation by berberine: molecular mechanism and network pharmacology analysis","volume":"128","author":"Wang","year":"2024","journal-title":"Phytomedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s41419-019-1706-y","article-title":"Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans","volume":"10","author":"Wu","year":"2019","journal-title":"Cell. Death Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e16556","DOI":"10.1371\/journal.pone.0016556","article-title":"Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis","volume":"6","author":"Xia","year":"2011","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ejphar.2011.07.036","article-title":"Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver","volume":"668","author":"Xing","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.1096\/fj.201802316R","article-title":"Berberine alleviates nonalcoholic fatty liver induced by a high-fat diet in mice by activating SIRT3","volume":"33","author":"Xu","year":"2019","journal-title":"Faseb. J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3173","DOI":"10.7150\/ijbs.62556","article-title":"Berberine modulates deacetylation of PPAR\u03b3 to promote adipose tissue remodeling and thermogenesis via AMPK\/SIRT1 pathway","volume":"17","author":"Xu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e0134172","DOI":"10.1371\/journal.pone.0134172","article-title":"Efficacy of berberine in patients with non-alcoholic fatty liver disease","volume":"10","author":"Yan","year":"2015","journal-title":"PLoS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11655-011-0668-4","article-title":"Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats","volume":"17","author":"Yang","year":"2011","journal-title":"Chin. J. Integr. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"913378","DOI":"10.3389\/fphar.2022.913378","article-title":"Berberrubine, a main metabolite of berberine, alleviates non-alcoholic fatty liver disease via modulating glucose and lipid metabolism and Restoring gut microbiota","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.7150\/ijbs.54604","article-title":"Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver","volume":"17","author":"Yu","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12967-015-0383-6","article-title":"Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles","volume":"13","author":"Yuan","year":"2015","journal-title":"J. Transl. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s12020-018-1689-y","article-title":"Berberine promotes glucose uptake and inhibits gluconeogenesis by inhibiting deacetylase SIRT3","volume":"62","author":"Zhang","year":"2018","journal-title":"Endocrine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11596-019-1997-3","article-title":"Berberine ameliorates high-fat diet-induced non-alcoholic fatty liver disease in rats via activation of SIRT3\/AMPK\/ACC pathway","volume":"39","author":"Zhang","year":"2019","journal-title":"Curr. Med. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12902-017-0165-7","article-title":"Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease","volume":"17","author":"Zhao","year":"2017","journal-title":"BMC Endocr. Disord."},{"key":"B53","doi-asserted-by":"publisher","first-page":"7287","DOI":"10.1039\/d2fo01009g","article-title":"Astragalus mongholicus polysaccharides ameliorate hepatic lipid accumulation and inflammation as well as modulate gut microbiota in NAFLD rats","volume":"13","author":"Zhong","year":"2022","journal-title":"Food Funct."},{"key":"B54","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","article-title":"Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway","volume":"141","author":"Zhu","year":"2019","journal-title":"Free. Radic. Biol. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1460643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:41:42Z","timestamp":1756453302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1460643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":54,"alternative-id":["10.3389\/fphar.2025.1460643"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1460643","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1460643"}}